• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GSK and CureVac to Restructure Collaboration into New Licensing Agreement

    7/3/24 2:40:00 AM ET
    $CVAC
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CVAC alert in real time by email
    • GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations

    • CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced

    LONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities.

    Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac currently have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Data generated to date for these candidate vaccines are promising and demonstrate their potential to be best-in-class new vaccines.

    Under the terms of the new agreement, GSK will assume full control of developing and manufacturing these candidate vaccines. GSK will have worldwide rights to commercialise the candidate vaccines. The agreement represents the latest step in GSK's ongoing investment in vaccine platform technologies, matching the best platform to each pathogen to develop best-in-class vaccines. mRNA is an adaptable vaccine technology with demonstrated application in emerging and constantly changing viral pathogens due to its ability to support rapid strain change. GSK continues to develop and optimize its mRNA capabilities through investments and partnerships, including in AI/ML-based sequence optimisation, nanoparticle design and manufacturing.

    CureVac will receive an upfront payment of €400 million and up to an additional €1.05 billion in development, regulatory and sales milestones and tiered royalties in the high single to low teens range. The new agreement replaces all previous financial considerations from the prior collaboration agreement between GSK and CureVac. CureVac further retains exclusive rights to the additional undisclosed and preclinically validated infectious disease targets from the prior collaboration together with the freedom to independently develop and partner mRNA vaccines in any other infectious disease or other indication. CureVac's ongoing patent litigation against Pfizer/BioNTech is unaffected by the new agreement.

    Tony Wood, Chief Scientific Officer, GSK said: "We are excited about our flu/COVID-19 programs and the opportunity to develop best-in-class mRNA vaccines to change the standard of care. With this new agreement, we will apply GSK's capabilities, partnerships and intellectual property to CureVac's technology, to deliver these promising vaccines at pace."

    Alexander Zehnder, Chief Executive Officer, CureVac said: "The collaboration with GSK has been instrumental in developing promising, late clinical-stage vaccine candidates, leveraging our proprietary mRNA platform. This new licensing agreement puts us in a strong financial position and enables us to focus on efforts in building a strong R&D pipeline."

    Completion of the new agreement remains subject to certain antitrust and regulatory approvals and customary closing conditions.

    About GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

    About CureVac

    CureVac (NASDAQ:CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.


    CureVac Media Contact
    Patrick Perez, Junior Manager Public Relations
    CureVac, Tübingen, Germany
    T: +49 7071 9883-1831
    [email protected]

    CureVac Investor Relations Contact
    Dr. Sarah Fakih, Vice President Corporate Communications and Investor Relations
    CureVac, Tübingen, Germany
    T: +49 7071 9883-1298
    M: +49 160 90 496949
    [email protected]

    GSK enquiries

    Media:

    Tim Foley

    +44 (0) 20 8047 5502

    (London)

    Simon Moore

    +44 (0) 20 8047 5502

    (London)

    Kathleen Quinn

    +1 202 603 5003

    (Washington DC)

    Alison Hunt

    +1 540 742 3391

    (Washington DC)

    Investor Relations:

    Nick Stone

    +44 (0) 7717 618834

    (London)

    James Dodwell

    +44 (0) 20 8047 2406

    (London)

    Mick Readey

    +44 (0) 7990 339653

    (London)

    Josh Williams

    +44 (0) 7385 415719

    (London)

    Camilla Campbell

    +44 (0) 7803 050238

    (London)

    Steph Mountifield

    +44 (0) 7796 707505

    (London)

    Jeff McLaughlin

    +1 215 751 7002

    (Philadelphia)

    Frannie DeFranco

    +1 215 751 4855

    (Philadelphia)

    Forward-Looking Statements CureVac

    This press release contains statements that constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential efficacy of the company's vaccine and treatment candidates and the company's strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "anticipate," "intend," "believe," "estimate," "plan," "seek," "project," or "expect," "may," "will," "would," "could," "potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.

    For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.

    SOURCE: CureVac



    View the original press release on accesswire.com

    Get the next $CVAC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CVAC
    $GSK

    CompanyDatePrice TargetRatingAnalyst
    CureVac N.V.
    $CVAC
    6/13/2025$5.00Buy → Hold
    Jefferies
    GSK plc
    $GSK
    6/3/2025Buy → Hold
    Berenberg
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    More analyst ratings

    $CVAC
    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GSK begins shipping influenza vaccine doses for the 2025-26 flu season

       GSK supports seasonal flu immunization in the US by shipping FLULAVAL (Influenza Vaccine) and FLUARIX (Influenza Vaccine) in advance of flu season GSK plc (LSE/NYSE:GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. According to the US Centers for Disease Control and Prevention (CDC), annual influenza vaccinatio

      7/10/25 9:13:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

      With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option

      6/24/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

      Grant funding will be provided to support national, state, and local non-profit organizations and community-based groups focused on lupus New resources and tools will support implementation of community-led programs designed to improve earlier diagnosis, enhance awareness of and access to evidence-based treatment, and/or advance communication between patients and providers Deadline for proposals is September 1, 2025 GSK plc (LSE/NYSE:GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN). "Too many people living with lupus face delays

      6/16/25 9:33:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CureVac downgraded by Jefferies with a new price target

      Jefferies downgraded CureVac from Buy to Hold and set a new price target of $5.00

      6/13/25 7:46:06 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlaxoSmithKline downgraded by Berenberg

      Berenberg downgraded GlaxoSmithKline from Buy to Hold

      6/3/25 7:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/10/25 6:21:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/9/25 6:20:55 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      7/8/25 6:28:40 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:38:14 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by GLAXOSMITHKLINE PLC

      3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      7/6/21 4:22:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

      4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

      6/23/21 6:14:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CureVac N.V. (Amendment)

      SC 13G/A - CureVac N.V. (0001809122) (Subject)

      2/14/24 5:01:40 PM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by GSK plc (Amendment)

      SC 13G/A - GSK plc (0001131399) (Subject)

      2/13/24 1:37:25 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CVAC
    $GSK
    Financials

    Live finance-specific insights

    See more
    • CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

      Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNONew off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccinesPositive Phase 2 data from seasonal influen

      11/12/24 7:20:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

      TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter and first nine months 2024 on Tuesday, November 12, 2024. The company will host a conference call and webcast on the same day at3 p.m. CET / 9 a.m. EST.Dial-in numbers to participate in the conference call:U.S. Toll-Free: +1-877-407-0989International: +1-201-389-0921Germany: 0800-182-0040 (landline access) / 0800-184-4713 (cell phone access)The live webcast link can be accesse

      11/7/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

      Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platformInitiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areasInvoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreementDosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMOStrengthening of Supervisory Board

      8/15/24 7:30:00 AM ET
      $CVAC
      Biotechnology: Pharmaceutical Preparations
      Health Care